1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6989127791DF450010025876C004CE5D5
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-managing-hostile-stakeholders-during-launch-breakthrough-new-medicine-working-with-kols-payers-activist-groups?opendocument
18
19opendocument
203.89.204.127
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Product Launch Excellence

Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine: Working with KOLs, Payers, and Activist Groups

ID: 5704


Features:

25 Info Graphics

10+ Metrics

10 Narratives


Pages/Slides: 33


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine: Working with KOLs, Payers, and Activist Groups”

STUDY OVERVIEW

Launching a new breakthrough medicine is often like a double-edged sword for pharma companies. While the drug could go on to achieve blockbuster status owing to factors such as fulfilling an unmet need or first-mover advantage, there is a significant likelihood of hostile responses from key stakeholder groups in case of an associated stigma or other controversy around the product.

Consequently, many pharma companies are developing rapid response teams to map and engage the full range of hostile stakeholder groups.

Best Practices, LLC engaged senior launch leadership from pharma companies and conducted extensive secondary research to identify effective strategies for managing hostile stakeholders during the launch of a breakthrough new medicine.

The study probes key aspects including: working with KOLs and HCPs; working with activist groups; and working with payer groups.

KEY TOPICS

  • Working with KOLs and HCPs
  • Working with Activist Groups
  • Working with Payer Groups

SAMPLE KEY FINDINGS

  • Show The Evidence: Social platforms can bring forward science, research, experts & advocates lobbying for fair treatment before government.
  • Sensitivity Mapping: Map the price and revenue curve under which payers will block or limit coverage – expecting 25-40% to act hostilely.

METHODOLOGY


Best Practices, LLC engaged and examined front-line executives at 11 companies across 9 therapeutic areas to conduct this analysis on hostile stakeholder management. Extensive secondary research was also conducted to identify industry best practices.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Bayer; Boehringer Ingelheim; Eli Lilly and Company; Gilead Sciences; GlaxoSmithKline ; Johnson & Johnson; Merck; Pfizer; Roche; Sprout Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.